Cooperative Agreement U10CA027469

This $8.58 million cooperative agreement from the Department of Defense's Uniformed Services University Medical Research Projects program (CFDA 12.750) supports the Gynecologic Cancer Center of Excellence (GYN-COE) Core from April 2021 through April 2023. The GYN-COE aims to identify molecular alterations in gynecologic cancers and develop novel strategies for prevention, early detection, and precision treatment through investigating carcinogenesis and drug resistance in pre-clinical and...

Federal Grant Award Summary The National Cancer Institute awarded Oraliva, Inc. a $400,000 Project Grant under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) effective September 1, 2025, through August 31, 2026, to develop a novel point-of-care (POC) diagnostic tool for gynecological screening in low-resource settings. Oraliva will leverage its artificial intelligence-linked cytomics-on-a-chip (ONC-INCYT) technology to create the first rapid, integrated human papillomavirus...

Federal Cooperative Agreement Summary The Georgia Center for Oncology Research and Education, Inc. received a $1.37 million Cooperative Agreement from the National Center for Chronic Disease Prevention and Health Promotion (NCCDPHP) under the Organized Approaches to Increase Colorectal Cancer Screening program (CFDA 93.800), effective August 30, 2025, through August 29, 2030. The Georgia Colorectal Cancer Control Program (GCRCCP) delivers evidence-based colorectal cancer screening...

The Department of the Army Medical Command awarded a $2,843,750 Project Grant to The Trustees of the University of Pennsylvania under the Military Medical Research and Development program (CFDA 12.420). The grant supports the Department of Defense Omics Consortium to Study the Origins of Ovarian Cancer (DOCSOOC) from August 15, 2022 to August 14, 2026. The Consortium will develop a pathology resource for pan-omic studies of tubal precursors to ovarian cancer. It will facilitate communication and...

Morphogenesis, Inc. was awarded a $1,200,000 Project Grant from the National Cancer Institute, part of the Department of Health and Human Services, to develop a low-cost topical immunotherapy formulation suitable for treating cervical cancer in low- and middle-income countries and low-resource settings in the United States. The funding supports optimization of Morphogenesis' IFX-HU2.1 plasmid DNA-based cream formulation for temperature stability using established methods and models. In vitro...

The National Cancer Institute awarded Massachusetts General Hospital (MGH) a Project Grant totaling $744,575 under the Cancer Cause and Prevention Research program (CFDA 93.393) on May 16, 2025, with performance through April 30, 2030. The grant supports research to define the genomic and biologic impact of LINE-1 (Long Interspersed Element-1) activity in fallopian tube epithelial cells and its contribution to high-grade serous ovarian cancer (HGSOC) pathogenesis. The research will investigate...

Federal Cooperative Agreement Award Summary Awarded by the National Cancer Institute under the Cancer Cause and Prevention Research program (CFDA 93.393), MedStar Health Research Institute Inc. received $2,677,863 on July 25, 2025, to develop and test implementation strategies for delivering practical geriatric assessment in community oncology settings. The project addresses a critical gap in cancer care for older adults, who will comprise 75% of the 22.2 million projected U.S. cancer...

The National Cancer Institute (NCI) awarded a $151,000 Project Grant under the Cancer Cause and Prevention Research (CFDA 93.393) program to The Medical University of South Carolina (MUSC) to investigate the role of polyploid cancer cells in high-grade serous ovarian carcinoma (HGSOC). The project aims to: 1) Define essential genes for the polyploid cancer cell lifecycle and its critical transition stages using CRISPR-Cas9 screening, and 2) Determine the expression of putative polyploid cancer...

The National Cancer Institute (NCI), through the Cancer Detection and Diagnosis Research program (CFDA 93.394), awarded a $678,228 Project Grant to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to develop GLISCAN - a multi-analyte, multi-mutation blood-based assay for rapid, sensitive molecular subtyping of gliomas. The 5-year project aims to optimize, verify, and validate the GLISCAN assay, which will quantify tumor mutations (TERT C228T/C250T,...

Federal Cooperative Agreement Summary Mayo Clinic received a $1.26M Cooperative Agreement from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393), effective April 1, 2026 through March 31, 2031. The award supports the Lymphoma Epidemiology of Outcomes (LEO) Cohort Study, a longitudinal epidemiologic research initiative designed to address unmet health needs of the growing non-Hodgkin Lymphoma (NHL) survivor population, currently exceeding...